NAYA's European Hub to Accelerate Clinical Development of its Astatine-211 Targeted Alpha Therapies and Multispecific Antibodies

MIAMI, FL AND PARIS, FRANCE / ACCESS Newswire / January 7, 2026 / NAYA Therapeutics, a clinical-stage biopharmaceutical company dedicated to pioneering the next generation of cancer therapies through the development of Astatine-211 (²¹¹At) targeted alpha therapies and immune redirecting multispecific antibodies, today announced that it has been selected to join the Paris-Saclay Cancer Cluster (PSCC)'s BOOST acceleration program and will establish its European research & manufacturing hub at Campus Grand Parc, the vibrant heart of the PSCC ecosystem. This strategic step will accelerate and scale the clinical development of its pipeline, strengthening its ability to translate breakthrough science into clinical impact.

NAYA's European hub will enable close collaboration with leading experts in Astatine-211 alpha therapeutics and multispecific antibodies. NAYA will establish an R&D lab, clinical development team, and its first European decentralized GMP manufacturing site for Astatine-211 therapeutics to support accelerated clinical trials at Gustave Roussy, one of the top 5 cancer centers in the world, along with other leading hospitals in the Greater Paris region. NAYA's supply model is designed to be scaled to major metropolitan areas around the world, with plans to deploy up to 10 decentralized sites over the next 2 years.

"We're thrilled to be establishing our European hub at the Paris Saclay Cancer Cluster, a unique ecosystem leveraging France's excellence and leadership in radiopharmaceuticals and oncology," commented NAYA CEO Dr. Daniel Teper. "NAYA is aiming to accelerate access to advanced oncology treatments for patients globally, translating the potential of novel modalities such as alpha therapies and multispecific antibodies into breakthrough medicines."

"Astatine-211's short half-life and clean decay enable precision killing while ensuring safety and minimal off-target exposure," added Dr. Désirée Deandreis, Head of the Nuclear Medicine Department at Gustave Roussy. "Astatine-211 alpha therapeutics show great promise in eradicating residual disease and micrometastasis in cancer patients, one of our greatest remaining challenges towards curing cancer. We look forward to collaborating with NAYA as they advance their clinical pipeline and deliver the transformative potential of alpha therapies to patients."

"We're excited to advance two immune cell redirecting multispecific antibodies to clinical development in Hepatocellular Carcinoma and Multiple Myeloma, validating pioneering research that originated through a European Consortium and the French National Center for Scientific Research (CNRS)," commented NAYA scientific co-founder and lead inventor of NAYA's antibody platform Dr. Jean Kadouche. "Multispecific antibodies have now matured as a primary modality in cancer and we look forward to addressing the needs of patients not responding to first-line immunotherapy."

About PSCC

The PSCC is a Scientific Cooperation Foundation (FCS), a private non-profit organization serving the public interest. Our founders include Gustave Roussy, Sanofi, Inserm, Université Paris-Saclay, and Institut Polytechnique de Paris, joined from the outset by key partners such as Unicancer, Institut Curie, AP-HP, and Medicen. These organizations reflect the quality and breadth of our network, covering the entire oncology value chain, from laboratory research to patient care.

From its inception, the PSCC has brought together academic, industrial, and institutional stakeholders to foster interactions and collaborations in oncology. We offer high-potential innovators a dedicated ecosystem of world-class experts, cutting-edge technologies, services, and infrastructures, along with unparalleled access to patient data and biological samples.

About NAYA

NAYA Therapeutics is a global biopharmaceutical company pioneering the next generation of cancer therapies, aiming to unlock deeper, more durable responses in patients not responding to current standard-of-care. NAYA's pipeline harnesses the transformational potential of two synergistic modalities, Astatine-211 (²¹¹At) targeted alpha therapies & immune redirecting multispecific antibodies, with an initial focus on hepatocellular carcinoma (HCC) and multiple myeloma. For more information, please visit www.nayatx.com.

NAYA Media & Investor Contact

Lyn Falconio, Chief Communications Officer
917-575-1844
lyn@nayatx.com

Paris-Saclay Cancer Cluster Contact

Catherine Kuttner, Chief Communications Officer
+33 (0)670617610

Marie Puvieux, ATCG Partners, Press Officer
+33 (0)610543672
communication@pscc.org

SOURCE: NAYA Therapeutics